Literature DB >> 34056037

Burden of Liver Cirrhosis in Portugal between 2010 and 2017.

João Manuel Silva1, Mário Jorge Silva2,3, Filipe Calinas2, Paulo Jorge Nogueira4,5,6,7.   

Abstract

INTRODUCTION: Liver cirrhosis is a prevalent disease in Portugal. Recent changes in alcohol consumption, as well as the wide use of direct-acting antivirals for hepatitis C since 2015, may be contributing to changes in the national burden of liver cirrhosis in the last few years.
OBJECTIVES: We aim to characterize the burden of cirrhosis in Portugal between 2010 and 2017. PATIENTS AND METHODS: We analyzed all hospital admission episodes due to cirrhosis in Portugal Mainland between 2010 and 2017, registered in the national Diagnosis-Related Group database, according to etiology of cirrhosis. We also analyzed data on mortality and potential years of life lost from liver cirrhosis and chronic liver disease, retrieved from Statistics Portugal (National Institute for Statistics).
RESULTS: Between 2010 and 2017, a total of 51,438 admissions for liver cirrhosis occurred in Portugal. The annual number of admissions decreased (p = 0.044) during the analyzed period. The most frequent cause of cirrhosis was alcoholic liver disease, present in 78.9% of all admissions (n = 40,595), followed by chronic hepatitis C virus infection, present in 11.3% (n = 5,823). A male predominance was identified in the admissions for every analyzed cause of cirrhosis. Annual admissions for alcoholic cirrhosis remained stable (p = 0.075) during the 8-year period. The same stable tendency was observed in the number of admissions for cirrhosis caused by hepatitis C virus (p = 0.861) and alcohol plus hepatitis C virus infection (p = 0.082), although these admissions for hepatitis C-related cirrhosis increased until 2014-2015 and steadily decreased thereafter. Annual deaths due to liver cirrhosis and chronic liver disease decreased from 1,357 in 2010 to 1,038 in 2017 (p = 0.002). The number of potential years of life lost decreased as well in the period (p = 0.001).
CONCLUSION: The burden of cirrhosis, evaluated by hospital admissions, mortality, and potential years of life lost, decreased in Portugal between 2010 and 2017.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Alcoholic liver disease; Burden; Cirrhosis; Hepatitis B virus; Hepatitis C virus

Year:  2020        PMID: 34056037      PMCID: PMC8138255          DOI: 10.1159/000510729

Source DB:  PubMed          Journal:  GE Port J Gastroenterol        ISSN: 2387-1954


  28 in total

Review 1.  Benefits of curing hepatitis C infection.

Authors:  Rui T Marinho; Sofia Vitor; Jose Velosa
Journal:  J Gastrointestin Liver Dis       Date:  2014-03       Impact factor: 2.008

2.  A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

Authors:  Lisa I Backus; Derek B Boothroyd; Barbara R Phillips; Pamela Belperio; James Halloran; Larry A Mole
Journal:  Clin Gastroenterol Hepatol       Date:  2011-03-11       Impact factor: 11.382

Review 3.  Hepatitis C: Is eradication possible?

Authors:  Andrea Lombardi; Mario U Mondelli
Journal:  Liver Int       Date:  2019-01-10       Impact factor: 5.828

Review 4.  Burden of liver diseases in the world.

Authors:  Sumeet K Asrani; Harshad Devarbhavi; John Eaton; Patrick S Kamath
Journal:  J Hepatol       Date:  2018-09-26       Impact factor: 25.083

Review 5.  Epidemiology of hepatitis B in Portugal.

Authors:  Mário J Silva; João Valente; Tiago Capela; Pedro Russo; Filipe Calinas
Journal:  Eur J Gastroenterol Hepatol       Date:  2017-03       Impact factor: 2.566

6.  Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.

Authors: 
Journal:  Lancet Gastroenterol Hepatol       Date:  2017-03-15

Review 7.  Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies.

Authors:  Laura Pimpin; Helena Cortez-Pinto; Francesco Negro; Emily Corbould; Jeffrey V Lazarus; Laura Webber; Nick Sheron
Journal:  J Hepatol       Date:  2018-05-17       Impact factor: 25.083

Review 8.  What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?

Authors:  George N Ioannou; Jordan J Feld
Journal:  Gastroenterology       Date:  2018-10-24       Impact factor: 22.682

9.  The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

Authors: 
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-01-22

10.  Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals.

Authors:  Natasha K Martin; Peter Vickerman; Jason Grebely; Margaret Hellard; Sharon J Hutchinson; Viviane D Lima; Graham R Foster; John F Dillon; David J Goldberg; Gregory J Dore; Matthew Hickman
Journal:  Hepatology       Date:  2013-08-26       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.